Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors

Despite some promising results, the majority of patients do not benefit from T cell therapies, as tumors prevent T cells from entering the tumor, shut down their activity, or downregulate key antigens. Due to their nature and mechanism of action, oncolytic viruses have features that can help overcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Cervera-Carrascon, Victor, Quixabeira, Dafne C.A., Havunen, Riikka, Santos, Joao M., Kutvonen, Emma, Clubb, James H.A., Siurala, Mikko, Heiniö, Camilla, Zafar, Sadia, Koivula, Teija, Lumen, Dave, Vaha, Marjo, Garcia-Horsman, Arturo, Airaksinen, Anu J., Sorsa, Suvi, Anttila, Marjukka, Hukkanen, Veijo, Kanerva, Anna, Hemminki, Akseli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163046/
https://www.ncbi.nlm.nih.gov/pubmed/32322662
http://dx.doi.org/10.1016/j.omto.2020.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163046/
https://www.ncbi.nlm.nih.gov/pubmed/32322662
http://dx.doi.org/10.1016/j.omto.2020.03.003

Ejemplares similares